SRE
63
2
F
56
-3
BA
47
2
NWSA
62
-7
MU
28
-3
LRCX
37
-9
SE
60
-3
HSIC
45
5
EOG
56
-2
ROP
53
-9
FSLR
44
-2
BDX
56
10
DE
42
3
GILD
47
-8
TROW
47
-6
MSI
72
-3
VNO
46
-13
MNST
45
-21
CAT
59
-2
ETR
65
2
SRE
63
2
F
56
-3
BA
47
2
NWSA
62
-7
MU
28
-3
LRCX
37
-9
SE
60
-3
HSIC
45
5
EOG
56
-2
ROP
53
-9
FSLR
44
-2
BDX
56
10
DE
42
3
GILD
47
-8
TROW
47
-6
MSI
72
-3
VNO
46
-13
MNST
45
-21
CAT
59
-2
ETR
65
2
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.

Halozyme Therapeutics Price Quote

$45.65

Halozyme Therapeutics Key Stats

Sell
39
Halozyme Therapeutics (HALO) is a Sell
Day range:
$45.63 - $49.64
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
21.74
P/S ratio:
6.26
P/B ratio:
12.83%
Volume:
7.2M
Avg. volume:
1.7M
1-year change:
16.04%
Market cap:
$5.8B
Revenue:
$829.3M
EPS:
$3.02

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.34%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.72%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $403M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$222.4M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$300.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 22.41%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.54%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 156.62%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 72.13% 27.05%
Revenue: 34.28% 15.04%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.44
Upside from Last Price: 36.79%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    203.5M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders